Aurobindo Pharma announced that the US FDA classified its subsidiary Eugia Pharma’s unit-II in Bhiwadi as ‘Official Action Indicated’ after inspection. No business impact is expected. Shares of the company closed 0.80% up at ₹1,289.80 ahead of the announcement on…
Tech Mahindra London will acquire 20% of Tech Mahindra Arabia from Midad for SAR 83.7M. Expected by July 15, 2026, Tech Mahindra will hold 100% of Tech Mahindra Arabia.
Dow Jones Today | US Stock Market LIVE Updates: US stock futures moved lower on Tuesday (March 17) as crude oil prices climbed again, while investors evaluated US President Donald Trump’s appeal for allied nations to assist in safeguarding maritime…
Power Finance Corporation has approved a ₹1.6 lakh crore borrowing plan for FY27 and announced a fourth interim dividend for FY26, with March 23 set as the record date.
Nikunj Doshi, Managing Partner & CIO-PMS at Bay Capital Investments Advisors, says rising crude prices and global uncertainty are key risks, but markets tend to recover over time. He advises gradual accumulation during corrections, with a long-term positive view on…
Closing Bell: Indian markets ended higher in a volatile session, extending gains for a second day, as midcaps outperformed and market breadth improved, with auto stocks and select heavyweights leading the advance.
Jyoti Gupta, Senior Research Analyst at Nirmal Bang Institutional Equities, remains positive on defence, citing strong order books and execution visibility despite rich valuations, with picks like HAL and BEL. On cement, she sees limited gas impact but rising pet…
MOIL has mining operations spread across Nagpur and Bhandara districts of Maharashtra, and the Balaghat district of Madhya Pradesh. It produces various degrees of manganese ore.
Lupin and Zydus will co-market semaglutide injection in India. Lupin will use Semanext and Livarise, while Zydus will use Semaglyn, Mashema, and Alterme.
Eternal shares have corrected nearly 40% from its recent highs. Brokerage firm JM Financial said the stock now appears attractively valued at around 35x its estimated FY28 earnings.